Table 1.

Demographic and clinical characteristics of the study cohort

	Current	Former	Never	p value	Total
	(N = 9)	(N = 19)	(N = 19)		(N = 47)
Age at diagnosis
Mean (SD)	57.6 (5.22)	61.3 (10.6)	56.9 (9.07)	0.312	58.8 (9.26)
Decade of diagnosis
50–59	6 (66.7%)	7 (36.8%)	7 (36.8%)	0.212	20 (42.6%)
60–69	3 (33.3%)	5 (26.3%)	4 (21.1%)		12 (25.5%)
40–49	0 (0%)	2 (10.5%)	6 (31.6%)		8 (17.0%)
70–79	0 (0%)	5 (26.3%)	2 (10.5%)		7 (14.9%)
Gender
Female	1 (11.1%)	3 (15.8%)	1 (5.3%)	0.828	5 (10.6%)
Male	8 (88.9%)	16 (84.2%)	18 (94.7%)		42 (89.4%)
Race/Ethnicity
Asian	0 (0%)	1 (5.3%)	0 (0%)	1	1 (2.1%)
Caucasian	9 (100%)	18 (94.7%)	19 (100%)		46 (97.9%)
Primary tumor subsite
Base of Tongue	3 (33.3%)	9 (47.4%)	8 (42.1%)	0.838	20 (42.6%)
Tonsil	6 (66.7%)	9 (47.4%)	11 (57.9%)		26 (55.3%)
Overlapping Sites	0 (0%)	1 (5.3%)	0 (0%)		1 (2.1%)
Clinical T stage
T0	1 (11.1%)	2 (10.5%)	0 (0%)	0.462	3 (6.4%)
T1	2 (22.2%)	4 (21.1%)	3 (15.8%)		9 (19.1%)
T2	2 (22.2%)	7 (36.8%)	12 (63.2%)		21 (44.7%)
T3	3 (33.3%)	3 (15.8%)	3 (15.8%)		9 (19.1%)
T4	1 (11.1%)	3 (15.8%)	1 (5.3%)		5 (10.6%)
Clinical N stage
N0	1 (11.1%)	2 (10.5%)	0 (0%)	0.166	3 (6.4%)
N1	4 (44.4%)	5 (26.3%)	10 (52.6%)		19 (40.4%)
N2	3 (33.3%)	12 (63.2%)	7 (36.8%)		22 (46.8%)
N3	1 (11.1%)	0 (0%)	2 (10.5%)		3 (6.4%)
Clinical M stage
M0	9 (100%)	18 (94.7%)	19 (100%)	1	46 (97.9%)
M1	0 (0%)	1 (5.3%)	0 (0%)		1 (2.1%)
Overall clinical stage
I	3 (33.3%)	4 (21.1%)	8 (42.1%)	0.658	15 (31.9%)
II	4 (44.4%)	12 (63.2%)	8 (42.1%)		24 (51.1%)
III	2 (22.2%)	2 (10.5%)	3 (15.8%)		7 (14.9%)
IV	0 (0%)	1 (5.3%)	0 (0%)		1 (2.1%)

All patients were p16(+) and had untreated primary OPSCC.